Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stimulus Plans For Japan's Life Sciences Industries May Not Address Main Challenge - Bio Japan Conference

This article was originally published in PharmAsia News

Executive Summary

YOKOHAMA, Japan - Government agencies will initiate a plan in June 2011 to jumpstart Japan's lagging bioventure market, but government officials seem wary about being able to transform Japan's venture culture, a necessity for funding Japan's innovative technologies and medicines

You may also be interested in...



Daiichi Sankyo Withdraws Shipment Of Half The Company's Entire Influenza Vaccine Supply

TOKYO - Daiichi Sankyo Co. Ltd. will trash nearly half of its annual influenza vaccines after tests revealed batches were contaminated by avian reovirus. The company's joint venture with Kitasato Institute for vaccine production has had a rocky start since it began operations March 31, but vaccines play a small role in the company's overall domestic sales, so impact is expected to be negligible

Daiichi Sankyo Withdraws Shipment Of Half The Company's Entire Influenza Vaccine Supply

TOKYO - Daiichi Sankyo Co. Ltd. will trash nearly half of its annual influenza vaccines after tests revealed batches were contaminated by avian reovirus. The company's joint venture with Kitasato Institute for vaccine production has had a rocky start since it began operations March 31, but vaccines play a small role in the company's overall domestic sales, so impact is expected to be negligible

Angels Angle In Biotech

Biotechnology hasn't traditionally been an area of great interest to angel investors, the well-off individuals who invest only their own money in startups.

Related Content

UsernamePublicRestriction

Register

SC073465

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel